The best indicator for Vertex Pharmaceuticals (VRTX)
We backtested 20 indicators across daily, weekly and hourly charts on real Vertex Pharmaceuticals (VRTX) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
Williams %R
On the weekly chart, this is the strongest risk-adjusted edge we found for Vertex Pharmaceuticals (VRTX) over ~35.0 years — trailing buy-and-hold by 2.7% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | Williams %R ✓ | Weekly | 11.4% | 0.48 | -63.1% | 75.0% | 56 | -2.7% |
| 2 | WaveTrend (8/6/4) ✓ | Weekly | 10.5% | 0.46 | -71.0% | 71.9% | 32 | -3.5% |
| 3 | Stochastic ✓ | Daily | 9.7% | 0.44 | -68.8% | 67.5% | 191 | -4.5% |
| 4 | Bollinger Mean-Reversion ✓ | Weekly | 7.6% | 0.43 | -56.6% | 80.8% | 26 | -6.5% |
| 5 | Stochastic ✓ | Weekly | 9.0% | 0.43 | -61.7% | 71.1% | 38 | -5.1% |
| 6 | Money Flow Index ✓ | Daily | 8.8% | 0.41 | -66.1% | 73.9% | 46 | -5.3% |
| 7 | WaveTrend (8/6/4) ✓ | Daily | 8.4% | 0.4 | -79.0% | 63.6% | 132 | -5.7% |
| 8 | Williams %R ✓ | Daily | 7.8% | 0.39 | -69.0% | 69.1% | 236 | -6.3% |
| 9 | Holy Grail Confluence ✓ | Daily | 7.6% | 0.39 | -66.8% | 71.4% | 49 | -6.5% |
| 10 | Bollinger Mean-Reversion ✓ | Daily | 6.9% | 0.38 | -62.8% | 68.1% | 144 | -7.2% |
| 11 | ADX / DMI ✓ | Daily | 6.6% | 0.36 | -60.9% | 40.4% | 228 | -7.5% |
| 12 | EMA 50/200 Cross ✓ | Daily | 3.8% | 0.29 | -78.8% | 36.7% | 30 | -10.3% |
| 13 | MACD | Daily | 3.5% | 0.28 | -78.4% | 39.0% | 351 | -10.6% |
| 14 | CCI ✓ | Daily | 3.9% | 0.28 | -79.1% | 68.3% | 167 | -10.2% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Vertex Pharmaceuticals (VRTX), Williams %R on the weekly timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.